Evaluation of HTLV-I and HCV Prevalence in Non-Hodgkin’s Lymphoma

Maryam Rastin¹, Ali Reza Khoee², Nafiseh Tabasi¹, Akram Sheikh¹, Saeed Ziaolhaghi¹, Elham Esmaeeli¹, Shahrzad Zamani¹, Mahdieh Khazaei¹, Mahmoud Mahmoudi *¹

¹Immunology Research Centre, BuAli Research Institute, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
²Department of Pathology, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

© 2013 mums.ac.ir All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ARTICLE INFO

ABSTRACT

Objective(s): Non-Hodgkin’s lymphoma (NHL) is a lymphoproliferative malignancy in which cells undergo microscopic changes with unknown etiology, and risk factors such as age, sex, genetic and environmental factors are involved. The relationship between the presence of infectious agents and the development of lymphoproliferative diseases has been an interesting research topic. HTLV-I (Human T Cell Lymphotropic Virus Type-I) predisposes the infected individuals to opportunistic neoplasms and lymphoid malignancies. HCV (Hepatitis C Virus) the etiologic agent of hepatitis C, is hepatotropic, and long-term infection with HCV can continuously stimulate and expand lymphocyte clones, resulting in further transformation and finally aggressive malignancies.

Materials and Methods: 54 tissue samples diagnosed with NHL were selected to be studied for the presence of HTLV-I and HCV viruses. DNA and RNA were extracted from samples, cDNA was synthesized and using specific primers presence of HTLV-I and HCV viruses were investigated by PCR and nested RT-PCR methods.

Results: In 10 out of 54 (18.8%) samples (7 men and 3 women), HTLV-I was present, and 4 out of 54 (7.4%) samples (3 men and one woman) were positive for HCV.

Conclusion: Based on our results, it is recommended that in patients with NHL, infection with HTLV-I and HCV viruses need to be screened.

Introduction

Non-Hodgkin’s lymphoma (NHL) is a lymphoproliferative malignancy in which many microscopic changes is seen in the cells of patients, during which T or B lymphocytes undergo malignant transformation (1). The etiology for these changes is unknown, but the risk factors such as age, sex, genetic and environmental factors have been involved (2). The relationship between the presence of some infectious agents and development of lymphoproliferative diseases has been an interesting research topic for the researchers, since associations have been reported between the presence of HTLV-I, Helicobacter pylori, EBV, HIV and HCV with various types of lymphoma (3).

HTLV-I (Human T Cell Lymphotropic Virus Type-I) is a retrovirus endemic in certain areas of the world, including in the north east of Razavi Khorasan Province, Iran (4). This virus causes Adult T Cell Leukemia/lymphoma among 2-4% of infected individuals, and is associated with lymphoid malignancies (5). HTLV-I predisposes the infected people to opportunistic neoplasms and lymphoid malignancies by severe suppression of their immune system. The mechanism of causing malignancy by HTLV-I virus is not clear, but it seems that the gene products of Tax region in virus enhance transcription of the
genes controlling cell growth factors such as IL-2 through activation of a number of transcription factors like NF-kB. This results in increased proliferation of T lymphocytes. In addition, Tax region reduces the expression level of some controlling genes such as β-Polymerase, thereby increasing chromosomal anomalies through increasing DNA transcription errors (1). Contact with HTLV-I virus in the first years of life, especially from mother to child through breastfeeding, is important in the occurrence of lymphoid malignancies.

HCV (Hepatitis C Virus) is the etiologic agent of hepatitis C. HCV is not only hepatotropic but also lymphotropic and sialotropic. In addition to liver, it can be found in lymph nodes, pancreas, adrenal gland, thyroid, spleen and bone marrow, and therefore it seems to be able to reproduce and replicate in extrahepatic sites (7). HCV infection is associated with a wide range of immunological disorders and extrahepatic diseases such as type II and III cryoglobulinemia, NHL, membranoproliferative glomerulonephritis, autoimmune thyroiditis, and so forth (8). The role of HCV in development of the above diseases is not clear, but long-term infection with HCV can continuously stimulate and expand lymphocyte clones resulting in further mutation and transformation and finally aggressive malignancies such as NHL.

The protein in core region of HCV has shown to have severe transactivating activity, activating certain oncogenes. HCV may also cause transformation of the infected cells like lymphoid cells. Recently, a specific receptor for HCV has been identified as CD81 on hepatocytes and lymphocytes, which binds protein E2 in env region of the virus (9). The immune system status of the infected individuals, proliferation rate and mutation in virus together with genetic and environmental factors influence the type of diseases caused by HCV, so infection with this virus can cause a range of diseases like infectious disease or malignant lymphoma such as NHL.

Materials and Methods

In this study, 54 tissue samples which were diagnosed with NHL during the past forty years in the department of pathology, Imam Reza Hospital, Mashhad University of Medical Sciences were selected. After microscopic examination of the tissue samples and confirmation of diagnosis by a pathologist, two 5-micron sections from each tissue sample were prepared in two separate sterile microtubes.

**DNA extraction from paraffin embedded tissues**

One ml octane was added to the tissue sections and incubated at room temperature for 30 min (the microtubes were vortexed every 5 min), and was finally centrifuged 5 min at 8000 rpm, and the supernatant was discarded (this was done twice). Then, 0.5 ml pure ethanol was added to the precipitate in the bottom of tubes and centrifuged for 5 min at 8000 rpm, and the supernatant was discarded (this process was performed 2 times). After that, 2-3 drops of acetone was added to the resulting precipitate and incubated at a temperature of 50°C for 5 min with open lid to evaporate ethanol. 100 µl of digestion buffer (0.5% Tween, 1 mM EDTA, 5 mM Tris base) containing 200 µg/ml proteinase K enzyme was added and incubated at 37°C for 24 hr to perform enzymatic digestion. The proteinase K enzyme was inactivated after 10 min at 95°C. The microtubes were finally centrifuged for 1 min at 8000 rpm, and the supernatant containing extracted DNA was kept in a sterile tube at -20°C for PCR.

**RNA extraction from paraffin embedded tissues**

To extract RNA from Paraffin embedded tissues, deparaffinization and enzymatic digestion procedures were done as stated in the previous paragraph. To the obtained solution, containing intracellular nucleic acids, 1 ml TRIZOL (Roche) was added and kept at 4°C for 5 min. Then, 200 µl chloroform was added and vortexed for 15 sec, and again incubated at 4°C for 5 min and then centrifuged in 14000 rpm at 4°C. Three phases (layers) are formed in this step; the upper phase is aqueous and contains RNA. This phase was transferred to a sterile microtube, and an equal volume of isopropanol and 70% volume of 3M sodium acetate (pH=5.2) was added, kept on ice for 30 min and centrifuged for 10 min at 4°C in 12000 rpm. The supernatant was discarded, 1 ml 75% ethanol was added and put on ice for 10 min after vortexing, and centrifuged for 10 min in 8000 rpm. The supernatant was discarded and the precipitate was left in room temperature for 5-10 min to let the alcohol evaporate. Finally, 20 µl sterile DEPC treated water was added to the precipitate and put at 50°C for 5 min to dissolve RNA, and was used as a template for cDNA synthesis.

**cDNA synthesis**

Due to the unstable nature of RNA, cDNA should be synthesized from it by reverse transcription enzyme as soon as possible, and be subject to PCR. For synthesis of cDNA, the required materials were purchased from Fermentase Company, and cDNA synthesis procedure was performed according to the manufacturer’s recommendations.

Five µg (about 9 µl) of extracted RNA was added in a microtube, 1 µl (20 uM) random hexamer primer was added and the volume reached 1 ml using DEPC treated water. The microtube contents were mixed and incubated at 70°C for 10 min, and immediately were put on ice, then 4 µl of (5×) buffer, 0.5 µl RNase inhibitor, 2 µl dNTPs and 1.5 µl of DEPC treated water was added and placed at 25°C for 5 min. Then, 1 µl (40 units) of M-MuLV enzyme (reverse transcriptase) was added and was first put 10 min at 25°C and then 60 min at 42°C to synthesize cDNA. Finally,
the microtube was incubated for 10 min at 70°C until M-
MuLV enzyme was inactivated. The cDNA produced was
stored in -20°C freezer until the testing time. The pres-
ence of the HCV was assessed using Nested RT-PCR, and
presence of HTLV-I was evaluated by PCR.

PCR

PCR was performed using specific primers designed for
tax and LTR regions of HTLV-I and 5'-non coding (5NCR)
region of HC. The specificity of primers was checked us-
ing the information provided in the gene bank by the
blast software.

For the detection of HTLV-I genome, PCR was performed
with specific primers in 25 µl volume in 45 cycles by add-
ing 1-5 µg DNA, 0.3 µM each primers, 4mM MgCl₂, 200 µM
dNTPs and 1 unit Taq DNA polymerase with the following primers:

LT1: 5´-AAAAGCCTGGAGACAGTTCAGGAGG-3´,
LT2: 5´-TCGTATCCCAGGACGACCCCCCAA-3´,
HT1: 5´-GGATACCCAGTCTAGCTGTT-3´,
HT2: 5´-GAGCCGATAACGCGTCCATCG-3´

After amplification, a 451bp fragment was obtained for
LTR, and a 158bp fragment for tax regions of HTLV-I virus.

Discussion

HTLV-I is a human retrovirus associated with different
diseases like adult T cell leukemia/lymphoma (ATLL) and
chronic neurological disorders including HTLV-I associ-
ated myelopathy/Tropical spastic paraparesis (HAM/TSP)
(5). This virus weakens the immune system by infecting
Th lymphocytes. The gene products of virus Tax region
augment the transcription of controlling genes for cell
growth by activating a number of transcription factors
such as NF-κβ, resulting in increased proliferation of T
lymphocytes (6). In addition, the expression level of some
controlling genes such as β-polymerase is reduced, there-
by increasing chromosomal anomalies through the in-
crease in DNA transcription errors (1). The results of this
study show that there is 18.8% correlation rate between
NHL and the presence of HTLV-I, which is endemic in east-
ern regions of Iran. In a study performed on 32 patients in
1993 in Gabon, it was reported that HTLV-I was absent in 6
children with Burkitt’s lymphoma, while HTLV-I was pres-
ent in 26.9% of the adult patients with NHL (10). In a study
conducted in 2004 in Dominican Republic, the correla-
tion rate of HTLV-I with hematologic malignancies and
NHL was found to be 38.6% and 44.4%, respectively (11). In

Figure 1. PCR for amplification of tax region of HTLV-I virus
Lanes 1-7: Patients’ samples, Lane 8: positive control, Lane 9: negative con-
trol, Lane 10: 100 bp DNA Ladder

Figure 2. RT-PCR for HCV amplification
Lanes 1,2, 4, 5: patients’ samples
Lane 6: negative control
Lane 7: positive control
Lane 3: 50bp DNA Ladder
a study conducted in 1993 in Jamaica on 135 NHL patients, a high association rate of 63.3% was seen between HTLV-I presence and type T NHL (2), while in USA this association has been reported to be 4% (59). This difference in the rate of association between HTLV-I with non-Hodgkin’s lymphoma reported from different parts of the world seems to be due to the differences in the propagation of the virus in different regions. It seems that in endemic areas, there is a higher association with malignancies.

There are also several reports on the association between HCV infection and NHL, various researchers having reported different association rates. In a study conducted in Turkey in 2003, it has been stated that HCV is lymphotropic and sialotropic in addition to being hepatotropic, and its infection causes lymphotropic disorders with a reported 7.1% association rate with NHL (7). In another study in 2002, an association has been reported between HCV and NHL, cryoglobulinemia, membranous proliferative glomerulonephritis and Porphyria Cutanea Tarda (PCT). Those afflicted with these diseases were recommended to be screened for HCV infection (8). In a study in 1998, HCV replication in extrahepatic sites has been suggested, and HCV has been isolated from the liver, lymph nodes, pancreas, adrenal glands, thyroid, spleen and BM of infected people (12). In a study conducted in Brazil in 2002, the presence of HCV in patients with NHL was reviewed, and an association rate of 9% was reported with NHL (3). In our study, HCV was present in 7.4% of NHL patients. In a study conducted in 2004 in Spain, an association rate of 7% was also reported between HCV and non-Hodgkin’s lymphoma (13). In a study in California, 4.2% of NHL cases were sero positive for HCV, but in none of them RNA of the virus was detected (14).

These differences can be due to the environmental factors, race, and the presence of different genotypes, mutations or other factors. In most cases, genotype 2 of HCV has been detected in lymphoproliferative diseases, genotype 1b has been found in a few cases, and genotype 1a has not been found at all. Therefore, it could be concluded that perhaps the type of genotype is involved in the disease type following HCV infection. It seems that due to the differences in the genotypes prevalence in different regions, there are different association rates of HCV with malignancies.

**Conclusion**

In this study, we showed that the prevalence of HTLV-I virus, in this endemic in the northeast of Iran, and the prevalence of HCV virus have increased in NHL samples.

**Acknowledgment**

This study was granted by the Vice Chancellor of Research, Mashhad University of Medical Sciences, Mashhad, Iran.

**References**

1. Jeang KT, Widen SG, Semmes OJ, Wilson SH. HTLV-I trans-acting protein tax is a trans-repressor of the human Beta-polymerase gene. Science 1990; 247:1082-1084.

2. Manns A, Cleghorn FR, Falk RT, Hanchard B, Jaffe E, Bartholomew C, et al. Role of HTLV-I in development of non-Hodgkin lymphoma in Jamaica and Trinidad and Tobago. Lancet 1993; 342:1447-1450.

3. Chindamo MC, Spector N, Segadas JA, Pimenta G, Vanderborght B, Morais JC, et al. Prevalence of hepatitis C infection in patients with non-Hodgkin lymphomas. Oncol Rep 2002; 9:657-659.

4. Rafatpanah H, Hedayat Moghaddam MR, Farhimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi MR, et al. Prevalence of hepatitis B virus infection in patients with non-Hodgkin lymphomas. J Clin Virol 2011; 52:172-176.

5. Uchiyama T. Human T cell leukemia Virus type 1 (HTLV-I) and human diseases. Annu Rev Immunol 1997; 15:35-52.

6. Jeang KT, Giam CZ, Majone M. Life, death and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J Biol Chem 2004; 279:3993-3994.

7. Venkatesh N, Gulluk F, Arican N, Turlman S. HCV prevalence in Hodgkin and non-Hodgkin lymphoma cases. Turk J Gastroenterol 2003:14:737-176.
8. El-Seraq HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestation of hepatitis C among United States male veterans. Hepatology 2002; 36:1393-1404.
9. Flint M, Quinn ER, Levy S. In search of hepatitis C virus receptor(s). Clin Liver Dis 2000; 5: 873-893.
10. Delaporte E, Klotz F, Peeters M, Martin-Prevel Y, Bedjabaga I, Larouze B, et al. Non-Hodgkin lymphoma in Gabon and its relation to HTLV-I. Int J Cancer 1993; 53:48-50.
11. Adedayo OA, Shehu SM. Human T-cell lymphotropic virus type I (HTLV-I) and lymphoid malignancies in Dominica: a seroprevalence study. Am J Hematol 2004; 77:336-339.
12. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: specific detection of negative-strand viral RNA in various tissues. Hepatology 1998; 28:398-403.
13. Gisbert JP, Garcia-Buey L, Arranz R, Blas C, Pinilla I, Khorrami S, et al. The prevalence of hepatitis C virus infection in patients with non-Hodgkin’s lymphoma. Eur J Gastroenterol Hepatol 2004; 16:315-318.
14. Rabkin CS, Tess BH, Christianson RE, Wright WE, Waters DJ, Alter HJ, et al. Prospective study of hepatitis C viral infection as a risk factor for subsequent B-cell neoplasia. Blood 2002; 99:4240-4242.